Estrogen Plus Progestin Therapy Cardiovascular Disorders and Probable Dementia The WHI estrogen plus progestin substudy reported increased risks of DVT, pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral CE (0.625 mg) combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo [see Warnings and Precautions (5.1), and Clinical Studies (14.3)]
Metabolism & Elimination The metabolic fate and degradation pathways of MOTS-c remain incompletely characterized, representing a significant gap in pharmacokinetic understanding: Rapid plasma clearance observed in preclinical models, though precise half-life not definitively established Likely degradation through peptidase activity, though specific enzymes not identified No accumulation detected in chronic administration studies (animal models) Active metabolites not characterized
Caution Consult your physician If you are pregnant or nursing, or have a medical condition, or taking prescription drugs, or under the age of 18 years
Safety, Side Effects, and Monitoring Considerations The most common side effects of semaglutidenausea, vomiting, and mild gastrointestinal discomforttypically diminish within 2-4 weeks as your body adapts
Diabetes Metab Syndr (2020) 14(4):28992
Cellular Health and Energy Production Glutathione is integral to several metabolic processes: This treatment improves mitochondrial function which plays a crucial role in producing energy
